Mainz

• A Parallel-group (2-Arm), Randomized, Double-blind, 12-week Trial to Evaluate the Efficacy and Safety of MC2-25 Cream and MC2-25 Vehicle in … Not authorised
  2022-500044-38-00 4 Chronic Kidney Disease associated Pruritus
• A 3-month, phase 2, single-blind, randomised, no-treatment controlled study assessing efficacy and safety of Renaparin® for improvement of k … Not authorised
  2022-501389-23-00 4 end-stage renal disease or otherwise an insufficient kidney function
• A randomised, controlled trial to investigate the effect of a four/six week intensified pharmacological treatment for schizophrenia, major d … Not authorised
  2022-502185-24-00 5 Schizophrenia, schizoaffective disorder, schizophreniform disorder, ma
• Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not authorised
  2023-509861-19-00 4 Diffuse large B-cell lymphoma (DLBCL)
• A 3-month, phase 2, single-blind, randomised, no-treatment controlled study assessing efficacy and safety of Renaparin® for improvement of k … Pending
  2022-501389-23-02 4 end-stage renal disease or otherwise an insufficient kidney function
• Clinical trial to determine the efficacy and safety of AP707 in the treatment of Borderline Personality Disorder Pending
  2024-510873-11-00 4 Borderline personality disorder
• Extension Study of ACT-EARLY Pending
  2024-513676-18-00 5 Transthyretin Amyloidosis
• SIOP PNET 5 medulloblastoma Pending
  2024-513724-42-00 10 Medulloblastoma
• A study to evaluate the efficacy, immunogenicity, and safety of an RSV and hMPV VLP vaccine compared with placebo in participants aged 60 ye … Pending
  2024-513740-28-00 5 Respiratory Syncytial Virus and Human Metapneumovirus
• A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic marke … Pending
  2024-514682-19-00 5 Resected pancreatic ductal adenocarcinoma
• BEACON 2: A Multi-Arm, Multi-Stage Platform Trial For Relapsed Neuroblastoma Pending
  2024-516115-24-00 9 High risk relapsed neuroblastoma (relapsed or progressed after being d
• Comparison of neurocognitive outcome in two standard regimen for treatment of low-risk medulloblastoma (COGNITO-MB) Pending
  2024-517133-40-00 5 newly diagnosed, non-metastatic, SHH-activated, TP53-wt, non-MYC ampli
• Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients … Pending
  2024-517295-37-00 5 low and intermediate risk neuroblastoma
• Durvalumab (MEDI4736) in combination with consolidative radiochemotherapy and ablative stereotactic radiotherapy in extensive stage SCLC Pending
  2024-517937-41-00 4 extensive stage small cell lung cancer (SCLC)
• Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults with Non-cystic Fibrosis Bronchiectasis (NCFB) Pending
  2024-518821-13-00 4 Non-cystic Fibrosis Bronchiectasis
• A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy with Standard-of-Care Combination Regimens … Pending
  2024-519504-27-00 5 Relapsed Refractory Multiple Myeloma
• A clinical trial to assess the efficacy and safety of ADX-308, a new type of treatment for Geographic Atrophy (GA), an advanced stage of eye … Pending
  2025-521779-30-00 4 Geographic atrophy secondary to age-related macular degeneration
• A Study of LY4064809 With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) Pending
  2025-522791-92-00 5 Neoplasm Metastasis
• A Phase 2 trial to assess efficacy and safety of zasocitinib in moderate to severe hidradenitis suppurativa Pending
  2025-522831-33-00 4 Hidradenitis Suppurativa
• Clinical Study to Evaluate the Effects of Cevostamab in Patients with Lupus with or without Active Lupus Nephritis Pending
  2025-522904-26-00 3 Systemic Lupus Erythematosus (SLE) With or Without Active Lupus Nephri
• A study to investigate the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of a CD19/CD20 T-cell engager in participants with … Pending
  2025-522932-15-00 3 Systemic Lupus Erythematosus
• A Phase 3 extension study to assess the long-term safety and efficacy of remibrutinib in adult participants with moderate to severe hidraden … Pending
  2025-523259-72-00 5 Hidradenitis Suppurativa (HS)
• A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma. Pending
  2025-523285-25-00 5 Relapsed or Refractory Multiple Myeloma
• Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis Pending
  2025-523400-72-00 4 Cystic fibrosis

Showing 1–24 of 589 trials